

# Trojan Fund

### All data as at 31 May 2020

www.taml.co.uk


The investment objective of the Trojan Fund is to seek to achieve growth in capital (net of fees), ahead of inflation (UK Retail Price Index), over the longer term (5 to 7 years). The policy is to invest globally in government and public securities (such as sovereign debt and treasury bills), corporate bonds, equities and equity-related securities, private equity, precious metals, cash, cash Fund Size equivalents and deposits.

**Prices** 

343.61p 'O' accumulation shares

278.83p 'O' income shares


£4,814m



+8.5%

+2.1%

-3.1%



31/05/10 31/05/17 Total Return to 31/05/01 31/05/15 31/05/19 30/11/19 31 May 2020 Since launch 10 years 5 years 3 years 1 year 6 months +275.9% +75.0% +32.4% +12.0% +9.3% +5.5% Trojan Fund O Inc **UK Official Bank Base Rate** +49.7% +5.1% +2.5% +1.7% +0.6% +0.2% +68.0% +30.9% +13.2% +7.7% +1.2% +0.5% **UK Retail Price Index** +132.6% +6.9% -8.4% -11.2% -16.1% FTSE All-Share Index (TR)\* +80.2% Discrete Calendar Annual Returns 2001# 2002 2003 2004 2005 2006 2007 2008 2009 2010 +0.6% +4.1% +15.4% +10.3% +15.9% +12.0% +6.1% +1.1% +11.6% +14.4% Trojan Fund O Inc 2011 2012 2013 2014 2015 2016 2017 2018 2019 **2020** YTD

© FTSE International Limited 2020

#from 31 May 2001

Source: Lipper

Past performance is not a guide to future performance

+8.9%

+3.2%

+12.3%

+4.1%

Source: Lipper

+4.8%

+10.7%

### **May Commentary**

Your Fund returned +1.6% during the month compared to +3.4 % for the FTSE All-Share Index (TR).

Stock markets have cheered as Western governments began to ease lockdowns and the rate of new coronavirus cases in several countries slowed. We remain sceptical that the path to normalcy is as clear as the rally in share prices would

For those companies we own, earnings releases in the month have provided us with some insights into how they are We deliberately favour wellcapitalised companies with broad end-


market exposures, enabling them to endure and survive bouts of hardship. Two such examples are Medtronic and Agilent, both new to the portfolio over the past year, and performing positively.

Medtronic is the world's largest medical device manufacturer, with products to treat a wide range of illnesses from cardiovascular disease to diabetes. With COVID-19 leading to the deferral of many elective surgical procedures, Medtronic saw its sales decline -25% in the quarter. The majority of these sales are likely to return, as they cannot be deferred indefinitely without major risk to patients' health. Thanks to the strength of its balance sheet, Medtronic is able to continue investing behind its people and products, including remote-monitoring technology, an increasingly capability in the current environment.

-3.0%

Agilent meanwhile saw flat sales growth in the quarter, with demand for its testing equipment growing in health-related sectors, offsetting weakness in academic and energy-related sales. Geographic diversity also aided the resilience with its China business returning to growth. The company's financial strength enables it to continue investing behind its best opportunities.

### Return vs volatility since launch (31/05/2001)



Source: Lipper

Risk analysis since launch (31/05/01)	Trojan Fund O Inc	FTSE All-Share Index (TR)
Total Return	+275.9%	+132.6%
Max Drawdown <sup>1</sup>	-13.7%	-45.6%
Best Month	+8.9%	+9.9%
Worst Month	-4.7%	-15.1%
Positive Months	+66.7%	+58.3%
Annualised Volatility <sup>2</sup>	+6.3%	+13.9%

Source: Lipper 1. Measures the worst investment period <sup>2</sup> Measured by standard deviation of annual returns

Top 10 holdings (excluding government bonds)	% Fund
Gold Bullion Securities	7.6
Microsoft	5.4
Alphabet	4.0
Unilever	3.8
Nestlé	3.5
Diageo	3.1
Visa	3.0
Philip Morris	3.0
British American Tobacco	2.9
Medtronic	2.7
Total Top 10	39.0
17 other holdings	44.0
UK T-Bills	9.2
Cash	7.8
TOTAL	100.0

ource: Factset, holdings subject to change.

### **Fund Manager Awards**





### Fund information

A copy of the latest Prospectus and the KIID for each class (in English) upon which you should base your investment decision is available from Link Fund Solutions Ltd, the Fund's Authorised Corporate Director and Link Fund Administrators Ltd (Authorised and Regulated by the Financial Conduct Authority) on 0345 608 0950. The Trojan Fund is closed to new direct investments, but is still available to new investors through major fund platforms.

### Structure

Sub-fund of Trojan Investment Funds UCITS

### Investment Manager

Troy Asset Management Limited 33 Davies Street London W1K 4BP Tel: 020 7499 4030 Fax: 020 7491 2445

Fund Historic Yield ('O' Inc shares)

emaii: busdev@tami.co.uk	
Fund Manager Assistant Fund Manager	Sebastian Lyon Charlotte Yonge
Currency	£ Sterling
Launch Date	31 May 2001

### **Ongoing Charges**

'O' (ordinary) shares: 1.02% 'S' (charity) shares: 0.77%

### Dividend Ex Dates

1 August (interim), 1 February (final)

### Dividend Pay Dates

30 September (interim), 31 March (final)

## Authorised Corporate Director

Link Fund Solutions Limited Tel: 0345 608 0950

### ISIN

0.55%

GB0034243732 (O Inc), GB00B01BP952 (O Acc) GB00B05M9T27 (S Inc), GB00B05M9S10 (S Acc)

### Benchmarks

For more information on the benchmarks used please refer to the 'use of benchmarks' section in the fund information sheet, available from our <u>website</u>

### Dealing

Daily at noon Tel: 0345 608 0950

### Registrar

Link Fund Administrators Limited

### Auditor

Ernst & Young LLP

### Depositary

The Bank of New York Mellon (International) Limited

### ${\bf Bloomberg}$

CFTROJA\_LN (O Acc), CFTROJI\_LN (O Inc)

### SEDOL

B01BP95 (O Acc), 3424373 ( O Inc)

### Pricing

"O" share class prices published daily in the FT

### mportant Information

Fund performance data provided is calculated net of fees unless stated otherwise. Past performance is not a guide to future performance. Overseas investments may be affected by movements in currency exchange rates. The value of an investment and any income from it may fall as well as rise and investors may get back less than they invested. The historic yield reflects distributions declared over the past twelve months as a percentage of the fund's price, as at the date shown. It does not include any preliminary charge and investors may be subject to tax on their distributions. The yield is not guaranteed and will fluctuate. The fund may use currency forward derivatives for the purpose of efficient portfolio management. Neither the views nor the information contained within this document considers the properties of an object to tax or provide discretionary investment amagement services and should not be used as the basis of any investment decision. Any decision to invest should be based on information contained in the prospectus, the relevant key investor information document and the latest report and accounts. The investment policy and process of the fund(s) may not be suitable for all investors. If you are in any doubt about whether the fund(s) is/are suitable for you, please contact a professional advisor. References to specific securities are included for the purposes of illustration only and should not be construed as a recommendation to buy or sell these securities. The fund is authorised to invest in transferable securities and money market instruments insued or guarantees and should not be relied upon and may be subject to change without notice. Third party data is provided without warrant or insulation in the fund of shares of sub-funds of Trojan Investment fund ("Share registered for distribution to warranty is given as to its accuracy or completeness. The opinions of a property is given as to its accuracy or completeness. The party is given as to its accuracy or completeness. The party is given as to i